Robshaw & Julian Associates’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
$3.47M Sell
108,802
-2,425
-2% -$76.5K 2.49% 21
2017
Q1
$3.08M Sell
111,227
-395
-0.4% -$12.5K 2.22% 24
2016
Q4
$3.44M Buy
111,622
+7,984
+8% +$244K 2.54% 20
2016
Q3
$3.33M Sell
103,638
-211
-0.2% -$7.05K 2.47% 21
2016
Q2
$3.47M Sell
103,849
-17,511
-14% -$559K 2.65% 19
2016
Q1
$3.41M Buy
121,360
+106
+0.1% +$3.03K 2.57% 19
2015
Q4
$3.77M Sell
121,254
-15,067
-11% -$474K 2.92% 18
2015
Q3
$4.06M Sell
136,321
-17,338
-11% -$556K 3.43% 13
2015
Q2
$4.89M Sell
153,659
-2,810
-2% -$91.6K 3.75% 9
2015
Q1
$5.11M Sell
156,469
-785
-0.5% -$25K 3.84% 7
2014
Q4
$4.65M Sell
157,254
-1
-0% -$29 3.65% 14
2014
Q3
$4.41M Buy
157,255
+1,742
+1% +$48.9K 3.48% 15
2014
Q2
$4.38M Sell
155,513
-7,943
-5% -$226K 3.36% 12
2014
Q1
$4.98M Buy
163,456
+10,906
+7% +$325K 3.84% 7
2013
Q4
$4.43M Sell
152,550
-1,508
-1% -$43.9K 3.67% 8
2013
Q3
$4.2M Buy
154,058
+11,568
+8% +$315K 3.57% 9
2013
Q2
$3.79M Buy
+142,490
New +$3.94M 3.56% 10

Other funds holding PFE

Robshaw & Julian Associates's PFE Position: Q2 2017 in Review

Robshaw & Julian Associates reduced its Pfizer (PFE) stake by 2.2% in Q2 2017, selling an estimated $76.5K and leaving 108,802 shares worth $3.47M. The position accounts for 2.49% of the portfolio, ranked #21.

Robshaw & Julian Associates first reported a position in PFE in Q2 2013 and has held it in 17 quarters since. The position peaked at $5.11M in Q1 2015. 2,049 funds tracked by Wall St. Rank hold PFE as of Q2 2017.

  • Robshaw & Julian Associates held 108,802 shares of Pfizer worth $3.47M as of Q2 2017.
  • Robshaw & Julian Associates sold 2,425 Pfizer shares in Q2 2017, an estimated $76.5K.
  • Pfizer made up 2.49% of Robshaw & Julian Associates's portfolio in Q2 2017, its #21 holding.
  • Robshaw & Julian Associates first reported a position in Pfizer in Q2 2013 and has held it in 17 quarters since.
  • Robshaw & Julian Associates's Pfizer position peaked at $5.11M in Q1 2015.
  • 2,049 funds tracked by Wall St. Rank held Pfizer as of Q2 2017.

Based on Robshaw & Julian Associates's 13F filing for Q2 2017, filed 3 Aug 2017.